skip to Main Content

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

IRBM, Rainwater Charitable Foundation (RCF, based in Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) announce the start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. Financial details are not disclosed.
IRBM To Collaborate With MSD To Develop Peptides Against Coronavirus

IRBM to collaborate with MSD to develop peptides against coronavirus

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
Back To Top